MeSH Review:
Putamen
Meyer,
Houle,
Sagrati,
Carella,
Hussey,
Ginovart,
Goulding,
Kennedy,
Wilson,
Furukawa,
Kapatos,
Haycock,
Worsley,
Wong,
Kish,
Nygaard,
Shihabuddin,
Buchsbaum,
Hazlett,
Silverman,
New,
Brickman,
Mitropoulou,
Nunn,
Fleischman,
Tang,
Siever,
Hosomi,
Ban,
Naya,
Takahashi,
Guo,
Song,
Kohno,
Gill,
Patel,
Hotton,
O'Sullivan,
McCarter,
Bunnage,
Brooks,
Svendsen,
Heywood,
- Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. Freed, C.R., Breeze, R.E., Rosenberg, N.L., Schneck, S.A., Kriek, E., Qi, J.X., Lone, T., Zhang, Y.B., Snyder, J.A., Wells, T.H. N. Engl. J. Med. (1992)
- Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Dexter, D.T., Brooks, D.J., Harding, A.E., Burn, D.J., Muller, D.P., Goss-Sampson, M.A., Jenner, P.G., Marsden, C.D. Ann. Neurol. (1994)
- The behavioural and motor consequences of focal lesions of the basal ganglia in man. Bhatia, K.P., Marsden, C.D. Brain (1994)
- Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. Calon, F., Birdi, S., Rajput, A.H., Hornykiewicz, O., Bédard, P.J., Di Paolo, T. J. Neuropathol. Exp. Neurol. (2002)
- Neuroprotective effect of postischemic administration of sodium orthovanadate in rats with transient middle cerebral artery occlusion. Hasegawa, Y., Hamada, J., Morioka, M., Yano, S., Kawano, T., Kai, Y., Fukunaga, K., Ushio, Y. J. Cereb. Blood Flow Metab. (2003)
- Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Teicher, M.H., Anderson, C.M., Polcari, A., Glod, C.A., Maas, L.C., Renshaw, P.F. Nat. Med. (2000)
- NMDA receptor losses in putamen from patients with Huntington's disease. Young, A.B., Greenamyre, J.T., Hollingsworth, Z., Albin, R., D'Amato, C., Shoulson, I., Penney, J.B. Science (1988)
- Eye movements in monkeys with local dopamine depletion in the caudate nucleus. II. Deficits in voluntary saccades. Kori, A., Miyashita, N., Kato, M., Hikosaka, O., Usui, S., Matsumura, M. J. Neurosci. (1995)
- Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer's disease. Morrison, L.D., Cao, X.C., Kish, S.J. J. Neurochem. (1998)
- Chronic psychosocial stress reduces the density of dopamine transporters. Isovich, E., Mijnster, M.J., Flügge, G., Fuchs, E. Eur. J. Neurosci. (2000)
- Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. Nat. Med. (2003)
- Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Wilson, J.M., Kalasinsky, K.S., Levey, A.I., Bergeron, C., Reiber, G., Anthony, R.M., Schmunk, G.A., Shannak, K., Haycock, J.W., Kish, S.J. Nat. Med. (1996)
- Neuropeptide Y distribution in human brain. Adrian, T.E., Allen, J.M., Bloom, S.R., Ghatei, M.A., Rossor, M.N., Roberts, G.W., Crow, T.J., Tatemoto, K., Polak, J.M. Nature (1983)
- Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Greenamyre, J.T., Penney, J.B., Young, A.B., D'Amato, C.J., Hicks, S.P., Shoulson, I. Science (1985)
- PET studies and motor complications in Parkinson's disease. Brooks, D.J. Trends Neurosci. (2000)
- Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Kish, S.J., Shannak, K., Hornykiewicz, O. Ann. Neurol. (1987)
- Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Dure, L.S., Young, A.B., Penney, J.B. Ann. Neurol. (1991)
- Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Kuhl, D.E., Metter, E.J., Riege, W.H., Markham, C.H. Ann. Neurol. (1984)
- Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Hilker, R., Klein, C., Ghaemi, M., Kis, B., Strotmann, T., Ozelius, L.J., Lenz, O., Vieregge, P., Herholz, K., Heiss, W.D., Pramstaller, P.P. Ann. Neurol. (2001)
- Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Cannon, C.M., Abdallah, L., Tecott, L.H., During, M.J., Palmiter, R.D. Neuron (2004)
- Biochemical findings in a case of parkinsonism secondary to brain tumor. García de Y'ebenes, J., Gervas, J.J., Iglesias, J., Mena, M.A., Martín del Rio, R., Somoza, E. Ann. Neurol. (1982)
- Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia. Hosomi, N., Ban, C.R., Naya, T., Takahashi, T., Guo, P., Song, X.Y., Kohno, M. J. Cereb. Blood Flow Metab. (2005)
- Guanyl nucleotide interactions with dopaminergic binding sites labeled by [3H]spiroperidol in human caudate and putamen: guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites. Andorn, A.C., Bacon, B.R., Nguyen-Hunh, A.T., Parlato, S.J., Stitts, J.A. Mol. Pharmacol. (1988)
- Novel 4'-substituted and 4',4"-disubstituted 3 alpha-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. Newman, A.H., Kline, R.H., Allen, A.C., Izenwasser, S., George, C., Katz, J.L. J. Med. Chem. (1995)
- Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Seeman, P., Ulpian, C., Bergeron, C., Riederer, P., Jellinger, K., Gabriel, E., Reynolds, G.P., Tourtellotte, W.W. Science (1984)
- Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Meyer, J.H., Houle, S., Sagrati, S., Carella, A., Hussey, D.F., Ginovart, N., Goulding, V., Kennedy, J., Wilson, A.A. Arch. Gen. Psychiatry (2004)
- Preparation of [125I-Tyr27,Leu5]beta h-endorphin and its use for crosslinking of opioid binding sites in human striatum and NG108-15 neuroblastoma-glioma cells. Helmeste, D.M., Hammonds, R.G., Li, C.H. Proc. Natl. Acad. Sci. U.S.A. (1986)
- Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain. Waksman, G., Hamel, E., Fournié-Zaluski, M.C., Roques, B.P. Proc. Natl. Acad. Sci. U.S.A. (1986)
- Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. II. Transplant-induced behavioral recovery. Nikkhah, G., Cunningham, M.G., McKay, R., Björklund, A. J. Neurosci. (1995)
- Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. Kish, S.J., Shannak, K., Hornykiewicz, O. N. Engl. J. Med. (1988)
- Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment. Bacopoulos, N.C., Spokes, E.G., Bird, E.D., Roth, R.H. Science (1979)
- Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Shihabuddin, L., Buchsbaum, M.S., Hazlett, E.A., Silverman, J., New, A., Brickman, A.M., Mitropoulou, V., Nunn, M., Fleischman, M.B., Tang, C., Siever, L.J. Arch. Gen. Psychiatry (2001)
- Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Farde, L., Wiesel, F.A., Halldin, C., Sedvall, G. Arch. Gen. Psychiatry (1988)
- Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Tremblay, L.K., Naranjo, C.A., Graham, S.J., Herrmann, N., Mayberg, H.S., Hevenor, S., Busto, U.E. Arch. Gen. Psychiatry (2005)
- Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D., Beal, M.F. Ann. Neurol. (1997)
- Characterization and topography of high-affinity 125I-neurotrophin-3 binding to mammalian brain. Altar, C.A., Criden, M.R., Lindsay, R.M., DiStefano, P.S. J. Neurosci. (1993)
- Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Furukawa, Y., Kapatos, G., Haycock, J.W., Worsley, J., Wong, H., Kish, S.J., Nygaard, T.G. Ann. Neurol. (2002)
- LRRK2 expression linked to dopamine-innervated areas. Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., Olson, L. Ann. Neurol. (2006)
- Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine. Nikaido, T., Akiyama, M., Moriya, T., Shibata, S. Mol. Pharmacol. (2001)
- Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. Spencer, D.D., Robbins, R.J., Naftolin, F., Marek, K.L., Vollmer, T., Leranth, C., Roth, R.H., Price, L.H., Gjedde, A., Bunney, B.S. N. Engl. J. Med. (1992)
- Optimal effectiveness of BDNF for fetal nigral transplants coincides with the ontogenic appearance of BDNF in the striatum. Yurek, D.M., Hipkens, S.B., Wiegand, S.J., Altar, C.A. J. Neurosci. (1998)
- Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. Hu, X.T., Wachtel, S.R., Galloway, M.P., White, F.J. J. Neurosci. (1990)
- Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Miller, G.W., Staley, J.K., Heilman, C.J., Perez, J.T., Mash, D.C., Rye, D.B., Levey, A.I. Ann. Neurol. (1997)
- Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Kull, B., Svenningsson, P., Fredholm, B.B. Mol. Pharmacol. (2000)